title: Adult human olfactory epithelial-derived progenitors: a potential autologous source for cell-based treatment for Parkinson's disease.
abstract: Human adult olfactory epithelial-derived neural progenitors (hONPs) can differentiate along several neural lineages in response to morphogenic signals in vitro. A previous study optimized the transfection paradigm for the differentiation of hONPs to dopaminergic neurons. This study engrafted cells modified by the most efficient transfection paradigm for dopaminergic neural restriction and pretransfected controls into a unilateral neurotoxin, 6-hydroxydopamine-induced parkinsonian rat model. Approximately 35% of the animals engrafted with hONPs had improved behavioral recovery as demonstrated by the amphetamine-induced rotation test, as well as a corner preference and cylinder paw preference, over a period of 24 weeks. The pre- and post-transfected groups produced equivalent responses, indicating that the toxic host environment supported hONP dopaminergic differentiation in situ. Human fibroblasts used as a cellular control did not diminish the parkinsonian rotational deficits at any point during the study. Increased numbers of tyrosine hydroxylase (TH)-positive cells were detected in the engrafted brains compared with the fibroblast-implanted and medium-only controls. Engrafted TH-positive hONPs were detected for a minimum of 6 months in vivo; they were multipolar, had long processes, and migrated beyond their initial injection sites. Higher dopamine levels were detected in the striatum of behaviorally improved animals than in equivalent regions of their nonrecovered counterparts. Throughout these experiments, no evidence of tumorigenicity was observed. These results support our hypothesis that human adult olfactory epithelial-derived progenitors represent a unique autologous cell type with promising potential for future use in a cell-based therapy for patients with Parkinson's disease.
authors.affiliation: Department of Anatomical Sciences and Neurobiology, School of Medicine, University of Louisville, Louisville, Kentucky 40202, USA.
authors.forename: Meng
authors.initials: M
authors.lastname: Wang
authors.forename: Chengliang
authors.initials: C
authors.lastname: Lu
authors.forename: Fred
authors.initials: F
authors.lastname: Roisen
mesh_terms: D000328:Adult; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal; D002454:Cell Differentiation; D002465:Cell Movement; D002470:Cell Survival; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D002478:Cells, Cultured; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology; D059290:Dopaminergic Neurons / Q000166:cytology / Q000502:physiology; D005260:Female; D005347:Fibroblasts / Q000502:physiology / Q000637:transplantation; D006801:Humans; D058953:Neural Stem Cells / Q000166:cytology / Q000502:physiology / Q000637:transplantation*; D009831:Olfactory Mucosa / Q000166:cytology* / Q000502:physiology; D016627:Oxidopamine / Q000009:adverse effects; D010300:Parkinson Disease / Q000473:pathology / Q000628:therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014162:Transfection; D014182:Transplantation, Autologous; D014446:Tyrosine 3-Monooxygenase / Q000502:physiology
chemical_list: D016627:Oxidopamine; D000661:Amphetamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine